News

Biodesix Unveils Promising Data on VeriStrat Test for NSCLC

Biodesix Unveils Promising Data on VeriStrat Test for NSCLC

Biodesix Announces Breakthroughs on VeriStrat Test at ASCO

Biodesix, Inc. has announced exciting new data regarding their innovative VeriStrat test, which will be shared during the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting. This vital presentation is scheduled to commence at 2:30 PM ET on Saturday and features groundbreaking research pertaining to patients with non-small cell lung cancer (NSCLC).

The Significance of the VeriStrat Test

The VeriStrat test is designed to evaluate the immune response of patients to lung cancer by categorizing them as either Host Immune Classifier Hot or Cold. Those classified as Hot are considered to have a more favorable response, known as VeriStrat Good, while those classified as Cold experience a poorer response, referred to as VeriStrat Poor. With fresh insights from the INSIGHT study, which involved over 5,000 NSCLC patients, new findings reveal a significant leap in overall survival for those with VeriStrat Poor results when treated with a combination of immunotherapy and chemotherapy.

Impressively Improved Survival Rates

Data highlights a crucial breakthrough: patients exhibiting a VeriStrat Poor classification who underwent combined treatment have demonstrated more than triple the two-year survival rate compared to those who were treated with immunotherapy alone. Interestingly, patients identified as VeriStrat Good displayed similar survival rates, regardless of the treatment approach.

Expert Insights on Treatment Implications

Dr. Gary Pestano, Chief Development Officer at Biodesix, shed light on the implications of these findings: "Immunotherapy remains a beacon of hope in cancer treatments; however, responses vary among patients. Our recent findings imply that the VeriStrat test could become a pivotal tool for oncologists. It can aid in assessing treatment implications, allowing for more tailored approaches that could ultimately elevate patient care standards and outcomes."

Broader Applications of the VeriStrat Test

In addition to its efficacy in lung cancer cases, preliminary results from another ongoing study suggest the VeriStrat test's utility may extend to patients with a variety of solid tumors. This exciting potential could pave the way for improved patient stratification and targeted therapy across multiple cancer types, with further definitive data set to be published in the near future.

About Biodesix

Biodesix, Inc., a leading name in diagnostic solutions, is committed to enhancing clinical care and patient outcomes. Their offerings, including the Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance tests, are crucial in helping clinicians make informed decisions regarding personalized treatment pathways for patients suffering from lung disease. Their development services empower biopharmaceutical and life sciences institutions with the necessary scientific, technological, and operational support to elevate the diagnostic landscape.

Connect with Biodesix

For media inquiries, contact Natalie St. Denis, Director of Corporate Communications at Biodesix, via natalie.stdenis@biodesix.com or call (720) 925-9285. Investor contact can be directed to Chris Brinzey, Partner at ICR Healthcare at chris.brinzey@icrhealthcare.com, or reach out at (339) 970-2843.

Frequently Asked Questions

What is the VeriStrat test used for?

The VeriStrat test assesses a patient's immune response to lung cancer, which aids in predicting treatment outcomes.

How does the combined therapy improve patient survival?

Patients with VeriStrat Poor results experienced a significant increase in overall survival when treated with immunotherapy alongside chemotherapy.

What new findings were announced by Biodesix?

Biodesix unveiled data showing improved survival rates for NSCLC patients receiving combined immunotherapy and chemotherapy, with insights presented at ASCO.

Who presented the research at the ASCO Annual Meeting?

Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone, presented the findings from the INSIGHT study.

What other applications could VeriStrat have?

Preliminary indications suggest that the VeriStrat test may also be useful for guiding treatment in various types of solid tumors beyond lung cancer.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 15

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 41

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 35

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 347

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 10

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Melio’s AP Push Looks Useful, but Read the Fine Print

Updated Category News Views 87

Back-office drudgery rarely gets anyone’s pulse racing, yet it can quietly chew through a small business’s time and cash. That is why Melio’s latest recognition as Software Experts’ top pick for accounts payable automation deserves a look. The product pitch is straightforward: pull bills, approvals, payments and reconciliation into one workflow rather than leaving...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

Ragie Launches Advanced Agent Ready Features for Developers

Updated Category News Views 253

Ragie Introduces Innovative Agent Ready Features Ragie is excited to present its latest advancement: the introduction of Agent Ready capabilities. This launch focuses on empowering developers with tools for creating intelligent, context-aware agents. Enhanced features like Agentic Retrieval and support for Right-to-Left (RTL) languages enhance accessibility and robust...

Continue Reading
JNR Stellarc 100K: A Game-Changer in Refillable Vapes

Updated Category News Views 200

Introducing the JNR Stellarc 100K Refillable Vape JNR has officially launched the JNR Stellarc 100K, a remarkable modular refillable vape system that promises to redefine the vaping experience. Engineered for extreme endurance and superior safety features, the Stellarc 100K is set to offer unparalleled value to its users. This advanced vape is not just another product; it...

Continue Reading
Xiao-I Corporation Shareholders Encouraged to Join Class Action

Updated Category News Views 86

Xiao-I Corporation Shareholders Encouraged to Join Class Action Recent events have led to significant concerns for shareholders of Xiao-I Corporation. With allegations of misleading statements and inadequate disclosures surfacing, many shareholders find themselves at a crossroads. It is essential for investors who purchased shares during a specific period to explore their...

Continue Reading
Assessing Bristol Myers Squibb: Analyst Insights and Future Prospects

Updated Category News Views 138

Bristol Myers Squibb: A Low Valuation Opportunity BofA Securities has recently upgraded Bristol Myers Squibb Co. (NYSE: BMY) from a Neutral position to a Buy rating, indicating a positive outlook for the company driven by strong near-term catalysts. Analyst Jason Gerberry highlighted a compelling risk-reward scenario, especially as the company anticipates a flat...

Continue Reading
Carrier's Q3 Performance and Future Outlook: Key Insights

Updated Category News Views 237

Carrier Global Corporation's Q3 Earnings Overview Carrier Global Corporation (NYSE: CARR), a prominent innovator in climate and energy solutions, recently released its third-quarter earnings, showcasing performance that exceeded market expectations. The results highlight not only the financial stability of the company but also the strategic adjustments made to navigate...

Continue Reading